Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

133.43 -1.23 (-0.91%)
Streaming Delayed Price Updated: 2:56 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,180,901
Open 133.13
Bid (Size) 133.40 (3)
Ask (Size) 133.44 (2)
Prev. Close 134.66
Today's Range 132.48 - 133.67
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Should Quality Investors Include NYSE:NVO in Their Portfolio?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing? 
Via Chartmill
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+30.67%
+30.67%
1 Month
+7.69%
+7.69%
3 Month
+8.22%
+8.22%
6 Month
+38.37%
+38.37%
1 Year
+59.17%
+59.17%

More News

Read More
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Via Benzinga
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Via Benzinga
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
Via The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
Via The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Via Benzinga
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Via Benzinga
How Viking Therapeutics Stock Could 30x
Via The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
Via InvestorPlace
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now
Via InvestorPlace
Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Via InvestorPlace
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Via MarketBeat
'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
Via Benzinga
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.